Search: onr:"swepub:oai:gup.ub.gu.se/165792" >
The Effects of Rami...
The Effects of Ramipril in Individuals at Risk for Alzheimer's Disease: Results of a Pilot Clinical Trial
-
Wharton, W. (author)
-
Stein, J. H. (author)
-
Korcarz, C. (author)
-
show more...
-
Sachs, J. (author)
-
Olson, S. R. (author)
-
- Zetterberg, Henrik, 1973 (author)
- Gothenburg University,Göteborgs universitet,Institutionen för neurovetenskap och fysiologi, sektionen för psykiatri och neurokemi,Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry
-
Dowling, M. (author)
-
Ye, S. Y. (author)
-
Gleason, C. E. (author)
-
Underbakke, G. (author)
-
Jacobson, L. E. (author)
-
Johnson, S. C. (author)
-
Sager, M. A. (author)
-
Asthana, S. (author)
-
Carlsson, C. M. (author)
-
show less...
-
(creator_code:org_t)
- IOS Press, 2012
- 2012
- English.
-
In: Journal of Alzheimers Disease. - : IOS Press. - 1387-2877 .- 1875-8908. ; 32:1, s. 147-156
- Related links:
-
https://europepmc.or...
-
show more...
-
https://gup.ub.gu.se...
-
https://doi.org/10.3...
-
show less...
Abstract
Subject headings
Close
- Research shows that certain antihypertensives taken during midlife confer Alzheimer's disease (AD) related benefits in later life. We conducted a clinical trial to evaluate the extent to which the angiotensin converting enzyme inhibitor (ACE-I), ramipril, affects AD biomarkers including cerebrospinal fluid (CSF) amyloid-beta (A beta) levels and ACE activity, arterial function, and cognition in participants with a parental history of AD. This four month randomized, double-blind, placebo-controlled, pilot clinical trial evaluated the effects of ramipril, a blood-brain-barrier crossing ACE-I, in cognitively healthy individuals with mild, or Stage I hypertension. Fourteen participants were stratified by gender and apolipoprotein E epsilon 4 (APOE epsilon 4) status and randomized to receive 5mg of ramipril or matching placebo daily. Participants were assessed at baseline and month 4 on measures of CSF A beta(1-42) and ACE activity, arterial function, and cognition. Participants were middle-aged (mean 54 y) and highly educated (mean 15.4 y), and included 50% men and 50% APOE epsilon 4 carriers. While results did not show a treatment effect on CSF A beta(1-42) (p = 0.836), data revealed that ramipril can inhibit CSF ACE activity (p = 0.009) and improve blood pressure, however, there were no differences between groups in arterial function or cognition. In this study, ramipril therapy inhibited CSF ACE activity and improved blood pressure, but did not influence CSF A beta(1-42). While larger trials are needed to confirm our CSF A beta results, it is possible that prior research reporting benefits of ACE-I during midlife may be attributed to alternative mechanisms including improvements in cerebral blood flow or the prevention of angiotensin II-mediated inhibition of acetylcholine.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Medicinska och farmaceutiska grundvetenskaper -- Neurovetenskaper (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Basic Medicine -- Neurosciences (hsv//eng)
Keyword
- Alzheimer's disease
- angiotensin converting enzyme
- antihypertensive
- arterial function
- blood
- angiotensin-converting enzyme
- cerebrospinal-fluid
- receptor blockers
- cognitive decline
- ace-inhibitors
- dementia
- memory
- brain
- hypertension
- progression
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
To the university's database
- By the author/editor
-
Wharton, W.
-
Stein, J. H.
-
Korcarz, C.
-
Sachs, J.
-
Olson, S. R.
-
Zetterberg, Henr ...
-
show more...
-
Dowling, M.
-
Ye, S. Y.
-
Gleason, C. E.
-
Underbakke, G.
-
Jacobson, L. E.
-
Johnson, S. C.
-
Sager, M. A.
-
Asthana, S.
-
Carlsson, C. M.
-
show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Basic Medicine
-
and Neurosciences
- Articles in the publication
-
Journal of Alzhe ...
- By the university
-
University of Gothenburg